Approved products only, and it says so in the heading
Eight of the sixty-five sellers here publish brand-name prices and no compounded price at all, and this is one of them. The programme heading says the products are FDA-approved GLP-1s, and there is no compounded lane hiding underneath.
That removes the largest single question in this category. You are not weighing a compounded preparation against an approved finished drug; you are buying the approved product and paying somebody to prescribe and manage it.
What replaces that question is a pricing question, and it is a real one. Approved products cost what they cost, and the range on this page runs from a figure competitive with compounded pricing to one several times higher, depending entirely on which presentation you end up on.
The oral ladder is the reason to read this row
The approved once-daily oral GLP-1 gets a full six-step dose ladder here, with the price at each step and, where a reduction applies, the figure it is reduced from. Almost nobody in this comparison publishes an oral dose ladder in public.
The value of a ladder is that it prices the treatment rather than the first month of it. A starting-at figure tells you the bottom of a range. A ladder tells you what happens as your dose climbs, which is the thing that decides a year's cost.
The seller also lists the approved oral semaglutide pill at a starting figure. Between the two, this is one of the few places a reader can compare two approved oral routes without starting an intake.
Three prices for one brand, and why that is correct
The same page labels three different figures with the same brand name and the same molecule. They are different presentations — a vial, a pen device and a second pen — and the gap between the cheapest and the most expensive is enormous.
Recording one figure for that brand would have been wrong, so this roster carries three rows and names the presentation in each. It is the reader's job to find out which presentation they are being prescribed, and it is the single most consequential question on this page.
The two approved semaglutide products carry a promotional rate for the first two months and a stated standing rate afterwards. The standing rate is what this roster records, with the promotion recorded separately as what it is.
Two bills, and the cheaper care rate has a year attached
The hero states the split in one line: a care subscription at one rate, and medication from another, paid separately. That is more honest than most of this field manages, and it means neither figure is the bill.
The advertised care rate requires a twelve-month commitment. Month to month costs substantially more, and the page publishes both, which is to its credit. Twenty of the sixty-five sellers here bill a membership apart from the medication, and reading their headline figures as comparable to an all-in price underrates every seller that charges once.
One trap is specific to this company. It runs a second, unrelated membership for its general marketplace, and that subscription has nothing to do with this programme. A figure found elsewhere on this site may belong to a different product entirely.
What is missing
No list of served states appears for this programme. The only state-shaped sentence on the page is a note that the care subscription does not cover lab work in certain states, which is a billing carve-out and not a coverage list. Thirty-three of the sixty-five sellers here publish no service area at all.
No individual prescribing clinician is named for the weight programme, and no pharmacy is named. On an approved-product row the pharmacy question matters less than it does on a compounded one, but the clinician question does not.
The mega-menu on the site carries several further figures that are not part of this programme and do not render as visible text. They were excluded here, and one of them would have read as a second, conflicting weight-loss price if it had not been.
Sesame Care's published pricing
| Medication | Price | Verified |
|---|---|---|
| Orforglipron (brand) | $149/moFrom, per month, for the medication only — the care subscription is billed separately. The page prints the whole ladder: "0.8 mg: $149 · 2.5 mg: $149, previously $199 · 5.5 mg: $199, previously $299 · 9 mg: $299 · 14.5 mg: $349, or $299 with Foundayo™ Self-Pay Journey Program pricing · 17.2 mg: $349, or $299". | September 2026source |
| Semaglutide (brand) | $149/moFrom, per month, for the medication only: "New Wegovy® pill · Semaglutide · from $149 per /mo". The hero states the split in one line — care from $59 a month, "medication from $149/mo (paid separately)". | September 2026source |
| Tirzepatide (brand) | $299/moFrom, per month, for the medication only, paid separately from the care subscription: "Zepbound® vial · Tirzepatide · from $299 per /mo". | September 2026source |
| Tirzepatide (brand) | $299/moFrom, per month, for the medication only: "New Zepbound KwikPen® · Tirzepatide · from $299 per /mo". A different presentation from the vial and from the pen, each priced separately on the same page. | September 2026source |
| Tirzepatide (brand) | $1086/moFrom, per month, for the medication only: "Zepbound® · Tirzepatide · from $1,086 per /mo". The same page prices the vial and the KwikPen far lower, so the presentation decides the bill. | September 2026source |
| Semaglutide (brand) | $349/moThe standing rate after a two-month promotional period, in the page's own words: "Eligible patients will pay $199 per month for the first two consecutive [months] … Wegovy® will cost $349 per month for all doses: 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg." | September 2026source |
| Semaglutide (brand) | $349/moThe standing rate after the same two-month promotional period: "Ozempic® will cost $349 per month for the 0.25 mg, 0.5 mg, and 1 mg doses." | September 2026source |
compareglp may earn a commission when a reader signs up with a provider through a link on this site. 4 of the 65 providers reviewed here are paid partners today; the other 61 are not. See how this works.
See Sesame Care's current price →Good fit if
- Readers who want an FDA-approved finished drug and no compounded option anywhere near the decision.
- Buyers interested in the approved once-daily oral GLP-1 who want the whole dose ladder rather than a starting figure.
- People who want the care fee and the medication priced as two separate things, stated before the intake.
- Readers comparing presentations of the same brand-name product, since three of them are priced separately here.
Look elsewhere if
- Anyone unwilling to commit to twelve months of care. The advertised care rate depends on it and the month-to-month rate is substantially higher.
- Readers who need their state confirmed before starting. No coverage list is published for this programme.
- Buyers who want one charge covering everything. Here the care and the drug are billed separately, and lab work is excluded in some states.
- People who want an individual prescribing clinician named before they pay.
How this review was verified
- Read the weight-programme page in a browser and audited every dollar element for computed opacity, visibility, inherited hidden state and a real laid-out rectangle before recording a figure.
- Excluded eight further figures in the site's mega-menu, all of which compute to hidden with no laid-out area. One of them duplicates and would have conflicted with the programme's real headline price.
- Recorded three separate rows for the three presentations of the same brand-name injection, because the page labels all three with the same brand and the same molecule at very different figures.
- Recorded the standing rate for the two approved semaglutide products and logged the two-month promotional rate separately as an introductory offer.
- Recorded the care subscription as a separate membership scoped to this programme only, and deliberately kept the site's general marketplace membership out of the row.
- Took every URL from the site's own link list rather than minting one. A plausible guess at its terms page returns a not-found response; the real path is different.
- Ran the agency's published warning-letter search on the company name and read every row it returned. None belongs to this company; the name is an ordinary food word and the search matches food producers. The count is deliberately not published, because on this name a count is not an answer. That search covers warning letters only, and untitled letters were not searched.